• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Effects of anti-TNF biologic drugs on uveitis severity in Beh?et patients: systematic review and Meta-analysis

    2022-05-15 05:40:38SomayehAbolhasaniAlirezaKhabbaziForooghHosseiniShivaGholizadehGhalehAzizShahriarAlipour
    關(guān)鍵詞:管理制度馬鈴薯司法

    INTRODUCTION

    Beh?et’s disease (BD) was first discovered by Hulusi Beh?et

    . The geographical distribution of BD is related to the Silk Road rout. The disease is widespread in Middle Eastern,Far Eastern and Mediterranean countries such as Iran, Turkey,Tunisia, China, and Japan

    . The highest incidence of BD is in Turkey (80 to 370 patients per 100 000 population). The prevalence of the disease in Japan is about 13.5 per 100 000 and in Iran 80 per 100 000

    . It is a vasculitis associated with oral and genital ulcers, skin lesions and ocular involvement

    .Ocular involvement is in the form of recurrent non-granulomatous uveitis that can affect the anterior and posterior chambers of the eye. Uveitis is usually bilateral

    . However, the intestine and the central nervous system can also be affected

    .

    Management and treatment of BD is a serious challenge due to different clinical aspects. Therefore, treatment should be proportional to the patient’s condition and severity of clinical symptoms

    . Colchicine and non-steroidal anti-inflammatory drugs are often used to treat joint and mucosal involvement.However, more aggressive methods and immune suppressive agents are needed to treat severe symptoms such as uveitis,retinal vasculitis, neurological and gastrointestinal involvement

    .Current treatment focuses on reducing inflammation and controlling the immune system. For severe manifestation of the disease, high dose corticosteroids are used

    .

    第一,在招投標(biāo)階段,招標(biāo)單位要保證招標(biāo)程序合法公平,盡量選擇信譽(yù)度高、技術(shù)過硬、有實(shí)力且報(bào)價(jià)相對(duì)較低的建設(shè)施工單位,嚴(yán)禁通過不合理方式獲取工程承包權(quán)及濫用私權(quán)行為的出現(xiàn)。第二,在工程建設(shè)過程中,承包商要結(jié)合施工合同的各項(xiàng)條款,采取科學(xué)有效的施工進(jìn)度管理措施,加強(qiáng)對(duì)分包事項(xiàng)等的監(jiān)督管理,同時(shí)監(jiān)理方要充分體現(xiàn)出自身的監(jiān)督職能作用,強(qiáng)化管理與控制,確保工程建設(shè)的順利開展。第三,在竣工驗(yàn)收階段,要根據(jù)合同約定的工程數(shù)量與質(zhì)量,并結(jié)合相關(guān)標(biāo)準(zhǔn)進(jìn)行驗(yàn)收,確保工程質(zhì)量的合格,防止因質(zhì)量不合格出現(xiàn)返工,甚至安全危險(xiǎn)因素等,進(jìn)而影響工程按期交付使用情況的發(fā)生。

    BD patients have high levels of proinflammatory cytokines such as IL-1, IL-2, IL-6, tumor necrosis factor (TNF-α), IL-12,IL-17, IL-18, and IL-23R

    . TNF-α is an inflammatory cytokine that plays a role in homeostasis and immune response and in fact, it plays a major role in autoimmune diseases pathogenesis

    . This cytokine is encoded in the class 3 region of the HLA complex adjacent to HLA-B

    . TNF-α is secreted by many types of cells such as macrophages,monocytes and lymphocytes

    . Anti-TNF drugs are a group of medications that suppresses the physiologic response to

    隨著油田企業(yè)業(yè)務(wù)的開展,檔案資料的內(nèi)容也逐漸增加,給檔案管理工作帶來了更高的難度。此外,對(duì)于油田企業(yè)的檔案來說,不僅僅需要做好保存工作,而且要挖掘檔案的潛在價(jià)值,為當(dāng)前工作更高質(zhì)量、更高效率地開展提供必要的借鑒。而這些工作的開展,都離不開一套完善的檔案信息化管理制度。由于油田企業(yè)對(duì)于檔案管理工作重視不足,配套的信息化管理制度也沒有建立起來。有些企業(yè)即便是有檔案信息化數(shù)據(jù)運(yùn)行管理制度,在實(shí)際工作中沒有嚴(yán)格執(zhí)行,管理制度形同虛設(shè),檔案管理人員工作中存在較大的隨意性。

    TNF-α. The medications in this class include infliximab,etanercept, adalimumab, certolizumab pegol and golimumab.Infliximab, adalimumab, and golimumab are monoclonal antibodies against TNF-α. Etanercept is a soluble, divalent TNF-α receptor that binds to TNF-α to prevent it from binding to its receptor on the cell. Certolizumab pegol is the antigenbinding fragment (Fab’) of a humanized monoclonal antibody that has been conjugated to polyethylene glycol. Induction of antibodies against TNF is largely dependent on its structure,chimeric drugs have a higher capacity to stimulate the immune system than human drugs

    .

    The essential purposes in the management of patients with Beh?et’s uveitis are fast elimination of visual inflammation,avoidance of recurrent attacks, getting of whole remission,and maintenance of vision. Corticosteroids are generally used for the treatment of episodes of inflammation; however, their long-term use is associated with unacceptable side effects.Relapses are normal in the setting of steroid mono-therapy,and conventional immunosuppressive drugs have usually been used for long-term treatment

    .

    The combination of azathioprine and cyclosporine is more impressive than is immunotherapy with either factor, or combination therapy is used as a severe immunosuppressive regimen for the treatment of patients with severe Beh?et’s uveitis

    . In addition, we did not find any studies comparing infliximab with steroids. However, in some studies, infliximab was compared with cyclosporine, and the results showed that following the use of infliximab, the conditions of ocular inflammation were greatly reduced

    .

    Anti-TNF drugs that has been approved for treatment of rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis and has been used for the treatment of uveitis in BD with promising results

    . In general, anti-TNFs such as infliximab have been used to treatment uveitis, and anti-TNFs such as etanercept have been used to treat skin lesions

    . Some studies have suggested that long-term use of biologic drugs can lead to infection in some patients. However, some other studies have shown that no side effects lead to infection of the skin, soft tissues and joints

    . In some other studies, it has been reported to cause cancer in people who have taken these drugs for a long time. But in general, none has been proven

    .However, due to inconsistent results of the present studies and the lack of systematic study, this study is intended to evaluate the therapeutic effects of anti-TNF agents in BD patients with ocular involvement.

    MATERIALS AND METHODS

    After determining the search keywords,including Beh?et’s disease, Beh?et’s syndrome, adamantiades-Beh?et’s disease, anti-TNF agents and uveitis, they were searched both using MeSH keywords and freely in the databases of MEDLINE, Scopus, CINHAL, Psycoinfo,Cochrane Library, Proquest. Iranmedex, SID, IranDoc, Magiran databases were also searched for information in Persian. In addition to the above databases, the list of selected study resources as well as related conferences was searched manually.

    早白堊世華北克拉通東部進(jìn)入破壞峰期,淺部地質(zhì)以伸展活動(dòng)為特征,廣泛出現(xiàn)斷陷盆地,而深部過程以巖石圈轉(zhuǎn)型與減薄為特征,主要表現(xiàn)形式為巖漿活動(dòng)[18]。

    All articles were searched until May 2020 and studies were included in our research that met the inclusion criteria and included: 1) were published by May 2020; 2) studies were designed pre and post anti-TNF drug treatment; 3) were consistent in terms of keywords (in the field of BD, anti-TNF drugs, visual acuity, conflict and ocular attack); 4) contained information of the original article type; 5)had sufficient information such as best-corrected visual acuity(BCVA) or decimal or visual acuity logMAR score.

    Exclusion criteria also included: 1) in terms of keywords in the title and abstract screening stage did not match; 2) review and duplicate studies were excluded; 3) studies unrelated to Beh?et and eye involvement and lacked visual acuity score; 4) nonhuman studies (for example in the mouse).

    After identifying the final articles, the articles were sorted by publication date. Before extracting the data,the tables required for this study were designed based on the required criteria in the extraction table in excel software environment. Then, two authors separately and independently extracted the required data from the final selected articles based on pre-prepared tables.

    馬鈴薯品種、種植地土壤營(yíng)養(yǎng)、栽植方式等均會(huì)對(duì)播種密度產(chǎn)生直接影響,而播種密度又會(huì)直接影響馬鈴薯的產(chǎn)量及品質(zhì)。通常情況下早熟型馬鈴薯品種播種密度要稍大于晚熟型品種,育種馬鈴薯密度要高于商品馬鈴薯;制作淀粉的種植密度要大于制作薯?xiàng)l的種植密度。

    According to the contents mentioned in this section, in the first stage after the initial search, the number of articles included in the study was 1504, of which 523 were duplicate articles(981 articles remaining). Finally, according to the mentioned criteria, only 15 articles were found to be completely relevant,of which 12 articles were included in the analysis related to the visual acuity criterion (Figure 1).

    The visual prognosis in BD is affected by severe recurrence of uveitis. Recurrent attacks of ocular inflammation lead to structural changes that may lead to visual impairment and even blindness in patients if not treated promptly and appropriately. The main goal of Beh?et’s uveitis management is to quickly eliminate inflammation inside the eye, prevent recurrent attacks and maintain vision in these patients. TNF-α is a factor that plays a pivotal role in the development and maintenance of the inflammatory response, even though the specific etiopathogenesis of BD has not yet been elucidated but many experimental studies have shown that TNF-α plays an important role in the progression and persistence of ocular inflammation in BD

    . Therefore, in order to better understand which anti-TNF drugs have an effective therapeutic role in BD, we conducted this systematic review and Metaanalysis of data and pooled results.

    After fully extracting the data related to our articles, it was found that only the visual acuity index has been reported in most articles and is common to them and we lastly selected this index for the Meta-analysis. Finally, in case of discrepancies between the data, it was discussed until the same result was reached.

    We assessed the quality of the involved studies using the Cochrane Collaboration’s tool for assessing the risk of bias

    . In this reading, selected studies were judged based on the following criteria: bias related to patient selection (“selection bias”) which is determined based on the complete description of patient selection and their inclusion and exclusion criteria. If patients are carefully selected, they will be considered low risk in terms of bias risk. Measurement bias, which in this study is related to methods of measuring ocular involvement and ocular inflammation and score related to visual acuity. If precise methods are used, the risk is considered low. Follow-up bias, which refers to the length of the follow-up period. If it is mentioned in full detail, the risk is low in terms of bias. Exposure bias was considered as changes in ocular inflammation in patients. If the values related to visual acuity, eye inflammation and eye attacks are reported with great accuracy, it is reported as low risk. Finally,confounding bias is related to the data analysis and results.If the confounding factors such as gender, age, and drug use are carefully observed during the analysis of visual acuity and other factors related to eye inflammation, that study is considered low risk in confounding bias.

    We measured risk of bias using the Cochrane Collaboration’s tool for measuring the risk of bias in randomized trials. We classified bias according to five domains: sample selection bias, measurement bias, follow-up bias, exposure (ocular response) bias, and confounding (correlation) bias. We defined risk of bias as low, high, unclear risk. In most of the studies we reviewed, the inclusion and exclusion criteria were clearly mentioned, and most of them were in the low group. Most studies on the method section and method of assessment the severity of ocular inflammation and visual acuity score were fully explained. Therefore, these options were placed in the low-risk bias group.

    RESULTS

    Findings from Systematic Review

    After systematic review of articles,according to inclusion and exclusion criteria, finally 15 related articles were found, of which 12 articles were included in the Meta-analysis. One study was conducted in the Africa, six studies in European countries, and eight study in Asia. Of the 15 articles found, 9 articles examined the effect of infliximab and 4 articles about adalimumab and two others as a combination of two drugs. In these studies, the dose of infliximab was 5 mg/kg and adalimumab was 40 mg/subcutaneous/2wk. The mean age of the samples was 31.0y and the mean duration of illness and follow-up were 7.88y and 16.72wk, respectively. In these studies, the average duration of use of biological drugs was 18.21mo. The mean dose of prednisolone before and after biological treatments was reported in 5 studies and was 28.56 and 7.56 mg/kg, respectively.

    The electronic search, conducted until May 2020, resulted in 1458 abstracts, of which 378 abstracts were reviewed. Of those, 118 full texts were read and 15 found to be eligible (of these, 15 articles were selected for systematic review and among them 12 articles had the necessary properties for Meta-analysis). The reference lists of all 12 case-control were searched for relevant articles. Full texts of the major reviews found were read and their reference lists searched. The study characteristics of the patients enrolled in these studies are summarized in Table 1

    .

    Data for this study were extracted using a pre-designed table. Then, using comprehensive Metaanalyzed CMA.2 software, the data were analyzed by random effect method and the heterogeneity of the studies and their distribution was evaluated and Forrest plot and Funnel plot diagrams were presented.

    The studies also showed that the follow-up range and length of patients is either fully explained or incomplete. Because of this, they were either low or high risk in terms of followup bias. The bias of ocular response (exposure bias) was fully focused in most studies. Therefore, the bias of this option was considered low risk. Finally, in most studies, confounding factors such as gender, age, and medication use were carefullyconsidered during the analysis of visual acuity and other factors associated with ocular inflammation. For this reason,in most of them, low-risk bias was considered. The risk of bias in each included study is summarized in Table 2 and Figure 2.

    The articles and documents obtained from the search were screened in several stages in terms of title, abstract and full text, and the final studies with inclusion criteria were selected.The studies were evaluated by 2 experts and using a checklist(PRISMA) in terms of the types of bias risks (selection,performance, report, attrition,

    .) as well as content, critique and low-quality studies were discarded. Also, in case of disagreement between the experts, the third person was used and a group discussion was held. Relevant data were then extracted from the studies using a designed table.

    Data was entered in Comprehensive Meta-Analysis (CMA) 2.2 (BioStat Inc., US)and random-effect models were used. Assessment of risk of bias in included studies has been considered. The visual acuity logMAR score as the primary outcome variable was expressed as continuous variables. Standard deviation was calculated using actual

    -values obtained from

    -tests quoted by Cochrane. For every study, we calculated the mean difference(MD) for the primary outcome visual acuity logMAR score using 95% confidence interval (95%CI). The outcome measures were pooled by use of the random-effect model.Heterogeneity was calculated using Cochrane’s

    statistic and quantified using the

    statistic. These indicated the proportion of variability across studies due to heterogeneity, rather than sample error. In the case of missing data, efforts to contact authors were made.

    把握了上述三類“道”義,我們不難看出作者的思想,這有助于對(duì)“道”的英譯。然而,文中“道”的含義廣博,尤其是儒道之“道”,很難在英語世界找到相應(yīng)的對(duì)應(yīng)詞,獲得傳神達(dá)意的得體譯本。筆者姑且選取劉師舜、楊憲益、戴乃迭夫婦以及羅經(jīng)國(guó)這三個(gè)經(jīng)典譯本(以下分別簡(jiǎn)稱劉譯、楊譯、羅譯),將對(duì)應(yīng)的“道”的譯文摘出,按上文“道”的釋義及分類順序分別列舉如下(粗體為筆者所加):

    Asymmetry assessment of the funnel plot was con ducted for publication bias only to showcase the sample interventions.There was a slight asymmetry in Begg’s funnel plot, we did not find any evidence of publication bias for visual acuity logMAR (Egger’s test

    =2.54,

    =0.05, Begg’s test

    =0.6,

    =0.54; Figure 4).

    The preliminary results indicate a nonsignificant reduction in visual acuity logMAR score (MD=-1.5 IU/L, 95%CI:-2.1, -0.01). However, significant heterogeneity was revealed among studies (

    =154.97,

    =92.9%,

    <0.001). Despite a high

    , results were pooled, as examination of these studies on a Forest plot indicated that the individual trial results were consistent in the direction of the effect (

    , MD and confidence intervals largely fell on one side of the null line;Figure 3). Characteristics of age, sex ratios, and baseline visual acuity were similar across all trials. Table 1 highlights the characteristics of the included studies.

    DISCUSSION

    These data include general data of articles (name of the first authors of the articles, name of the country of study, year of study, sample size, age of individuals, length of treatment,and length of follow-up), data related to interventions (type of drug used, drug dose, names of other drugs (steroid and nonsteroidal drugs), response data (BCVA score, ocular attacks,prednisolone dose pre and post anti-TNF drug used).

    由于本工程地下水位位于樁底以上,全干孔作業(yè)需要先行降低地下水位,實(shí)施難度大,成本花費(fèi)高,安全系數(shù)低,故不予考慮;濕孔作業(yè)能達(dá)到施工要求,但近年來,鄭州市環(huán)保要求高,鉆孔泥漿造成大量污染,儲(chǔ)存及運(yùn)輸難度大,不利于環(huán)境治理。故綜合考慮選擇半濕孔鉆孔作業(yè),既加快了進(jìn)度,減少了投入,又有利于環(huán)境治理。

    The TNF-α is a pro-inflammatory cytokine which can adjust immune cells’ activity in autoimmune diseases. Since BD is a kind of autoimmune disease, therefore, TNF-α plays a significant role in causing inflammation in BD

    . Research shows that high levels of TNF-α and its receptors are present in the serum or plasma of BD patients along with other proinflammatory cytokines

    . Accordingly, blocking the TNF-α pathway can be considered as the first or second-line valid treatment in BD patients with ocular symptoms and uveitis. Anti-TNF drugs as a new therapeutic approach are the strategic alternative to traditional safety immunosuppressant

    while the results of infliximab have been very encouraging for the treatment of severe uveitis in BD

    .

    (3)洗胃后心里護(hù)理。首先,為患者創(chuàng)造一個(gè)良好的病房環(huán)境,保護(hù)其隱私。同時(shí),安排家屬在身邊陪伴;其次,與患者采取一對(duì)一溝通模式,引導(dǎo)患者將內(nèi)心情緒全面化表達(dá)出來,做深入化心理疏導(dǎo)。幫助患者正確認(rèn)知自己,以采用積極的心態(tài)面對(duì)問題,提高其心理承受力、社會(huì)適應(yīng)力;

    The researchers showed that anti-TNF-α regulates peripheral blood CD4+ T cells in patients with posterior intraocular inflammation, which is associated with improved visual function. In one study, researchers have been found that infliximab injections in patients with BD reduced the number of TNF-secreting peripheral blood mononuclear cells

    , which in turn reduced eye attacks and improved vision in patients

    .

    This study confirmed the efficacy of anti-TNF therapy (infliximab or adalimumab) for treating refractory uveitis associated with BD. Also, the results related to the number of ocular inflammatory attacks in these patients have been shown that the number of attacks after the addition of biological anti-TNF therapies has decreased significantly as shown in earlier studies. Since the use of some drugs can interfere with the results of the study, so these studies were not included in the results and were excluded from our study. However, in most studies, patients have used the same drugs to treat the disease, and in the end, only the results of prednisolone,which had a decreasing trend, have been reported in some studies

    . The results of some previous studies on the effects of these drugs may seem contradictory. One of the main reasons for the contrary results of the studies may be due to the fact that the patients studied in this research used different immunosuppressive drugs, some patients have used corticosteroids, and others have used drugs such as colchicine,azathioprine, and cyclosporine. Also, the dose and duration of drugs use have varied in different people, and all of these can affect the final results of these studies. In general, most treatments are used to reduce the dose of steroid drugs, which these drugs (anti-TNF) have also been associated with a significant reduction in the use of steroid drugs.

    為貫徹落實(shí)《國(guó)家信息化發(fā)展戰(zhàn)略綱要》《“十三五”國(guó)家信息化規(guī)劃》《全國(guó)司法行政“十三五”發(fā)展規(guī)劃》,全面推進(jìn)司法行政信息化建設(shè)發(fā)展,司法部于2017年7月12日發(fā)布的《關(guān)于印發(fā)〈“十三五”全國(guó)司法行政信息化發(fā)展規(guī)劃〉的通知》(司發(fā)通[2017]75號(hào)),明確提出司法鑒定管理信息化的管理要求。因此司法鑒定機(jī)構(gòu)信息化建設(shè)是響應(yīng)國(guó)家司法行政信息化發(fā)展的要求。對(duì)于緊跟司法行政管理政策,提高機(jī)構(gòu)鑒定質(zhì)量和效率,增強(qiáng)鑒定機(jī)構(gòu)管理和服務(wù)能力,促進(jìn)信息公開和社會(huì)監(jiān)督,具有十分重要的意義。

    One of the main limitations of this study may be the relatively low sample size in the studies. Other limiting factors include confounding factors such as patients’ age, medications used,type of medication, and dose of medication before biological drugs are added. However, in some studies, these factors were considered as confounders and the final results were reported.In conclusion, however, the overall results of this study show that the use of biologic drugs (anti-TNF drugs) along with other therapeutic drugs, has been effective on patients’ visual acuity and has led to a significant improvement in them.Also, the amount of eye attacks in them has been significantly reduced. In addition, since the long-term use of corticosteroid drugs can be harmful, simultaneous use of biological drugs can reduce the dose of prednisolone.

    長(zhǎng)石礦物量較少(<5%),但礦物種類繁多,主要為鉀長(zhǎng)石,偶見有條紋長(zhǎng)石、微斜長(zhǎng)石和鈉長(zhǎng)石等。現(xiàn)主要對(duì)鉀長(zhǎng)石的嵌布特征描述如下:

    None;

    None;

    None;

    None;

    None.

    1 Bulur I, Onder M. Beh?et disease: new aspects.

    2017;35(5):421-434.

    2 Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH.Epidemiology of Beh?et disease.

    2012;20(5):324-335.

    3 Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E,Inanc M, Gül A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine,cyclosporine, and corticosteroids in Beh?et’s disease: an open-label trial.

    2005;52(8):2478-2484.

    4 Fabiani C, Sota J, Vitale A,

    . Cumulative retention rate of adalimumab in patients with Beh?et’s disease-related uveitis: a fouryear follow-up study.

    2018;102(5):637-641.

    5 Lopalco G, Emmi G, Gentileschi S,

    . Certolizumab Pegol treatment in Beh?et’s disease with different organ involvement: a multicenter retrospective observational study.

    2017;27(6):1031-1035.

    6 Vallet H, Riviere S, Sanna A,

    Efficacy of anti-TNF alpha in severe and/or refractory Beh?et’s disease: multicenter study of 124 patients.

    2015;62:67-74.

    7 Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H. A double-blind trial of depot corticosteroids in Beh?et’s syndrome.

    (

    ) 2005;45(3):348-352.

    8 Mendes D, Correia M, Barbedo M,

    . Beh?et’s disease - a contemporary review.

    2009;32(3-4):178-188.

    9 Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Beh?et’s disease.

    2012;11(10):699-704.

    10 Dilek K, Oz?imen AA, Saricao?lu H, Saba D, Yücel A, Yurtkuran M,Yurtkuran M, Oral HB. Cytokine gene polymorphisms in Beh?et’s disease and their association with clinical and laboratory findings.

    2009;27(2 Suppl 53):S73-S78.

    11 Alipour S, Nouri M, Khabbazi A, Samadi N, Babaloo Z, Abolhasani S,Farhadi J, Roshanravan N, Jadideslam G, Sakhinia E. Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Beh?et’s disease.

    2018;119(8):6614-6622.

    12 Abolhasani S, Gholizadeh Ghaleh Aziz S, Khabbazi A, Alipour S.Determination of the relationship between the severity of Beh?et’s disease and the expression and methylation of IL-10, IL-6 and IL-8 genes.

    2018;4(1):6-14.

    13 Alipour S, Sakhinia E, Khabbazi A,

    . Methylation status of interleukin-6 gene promoter in patients with Beh?et’s disease.

    (

    ) 2020;16(3):229-234.

    14 Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Beh?et’s disease, sarcoidosis, and noninfectious uveitis.

    2013;2013:286857.

    15 Aziz SGG, Aziz SGG, Khabbazi A, Alipour S. The methylation status of

    -α and

    promoters and the regulation of these gene expressions in patients with Beh?et’s disease.

    2020;25(5):384-390.

    16 Ate? A, Kinikli G, Düzgün N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Beh?et’s disease.

    2006;26(4):348-353.

    17 Emi Aikawa N, Carvalho JF, Artur Almeida Silva C, Bonfá E.Immunogenicity of anti-TNF-α agents in autoimmune diseases.

    2010;38(2-3):82-89.

    18 Kaklamani VG, Kaklamanis PG, editors.

    Elsevier; 2001.

    19 Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z,Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory beh?et uveitis.

    2017;25(1):71-75.

    20 Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M.Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh?et disease.

    2010;94(3):284-288.

    21 Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS.Infliximab therapy for the treatment of refractory ocular inflammatory disease.

    2007;125(7):895-900.

    22 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-tnf therapy in Crohn’s disease.

    2018;19(8):2244.

    23 Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P,Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh?et’s disease.

    2001;358(9278):295-296.

    24 Atzeni F, Gianturco L, Talotta R, Varisco V, Ditto MC, Turiel M,Sarzi-Puttini P. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?

    2015;7(4):353-361.

    25 Ding TN, Deighton C. Complications of anti-TNF therapies.

    2007;2(6):587-597.

    26 Higgins JP, Thomas J, Chandler J,

    .

    . John Wiley & Sons; 2019.

    27 Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C,Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Beh?et’s disease: a 24-month followup study.

    (

    ) 2007;46(7):1161-1164.

    28 Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G.One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh?et’s disease refractory to standard immunosuppressive drugs.

    2011;31(1):33-37.

    29 Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H,Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

    2012;56(6):536-543.

    30 Fabiani C, Vitale A, Emmi G,

    . Efficacy and safety of adalimumab in Beh?et’s disease-related uveitis: a multicenter retrospective observational study.

    2017;36(1):183-189.

    31 Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Longterm clinical outcomes in patients with refractory uveitis associated with Beh?et disease treated with infliximab.

    2013;21(6):468-474.

    32 Ho M, Chen LJ, Sin HPY, Iu LPL, Brelen M, Ho ACH, Lai TYY,Young AL. Experience of using adalimumab in treating sightthreatening paediatric or adolescent Beh?et’s disease-related uveitis.

    2019;9(1):14.

    33 Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R,Neumann R, Kramer M. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.

    2018;256(4):801-808.

    34 El Garf AK, Shahin AA, Shawky SA, Azim MA, Effat DA,Abdelrahman SK. Efficacy of infliximab in refractory posterior uveitis in Beh?et's disease patients.

    2018;40(2):93-97.

    35 Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Beh?et’s uveitis: a retrospective long-term followup study.

    2014;32(4 Suppl 84):S58-S62.

    36 Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H. Health- and vision-related quality of life in patients receiving infliximab therapy for Beh?et uveitis.

    2013;97(3):338-342.

    37 Ueda S, Akahoshi M, Takeda A,

    . Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Beh?et’s disease.

    2018;5(1):9-15.

    38 Bawazeer A, Raffa LH, Nizamuddin SHM. Clinical experience with adalimumab in the treatment of ocular Beh?et disease.

    2010;18(3):226-232.

    39 Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh?et’s disease on infliximab therapy.

    2011;95(9):1245-1250.

    40 Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V,

    . Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh?et’s disease: national multicenter study of 177 cases.

    2019;71(12):2081-2089.

    41 Hu YW, Huang ZH, Yang SZ, Chen XQ, Su WR, Liang D.Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Beh?ets’ disease-associated uveitis: a systematic review and meta-analysis.

    2020;11:941.

    42 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis.

    2015;60(6):575-589.

    43 Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S,Hamuryudan V, Yazici H. Short-term trial of etanercept in Beh?et's disease: a double blind, placebo controlled study.

    2005;32(1):98-105.

    44 Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

    2007;56(10):3248-3252.

    45 Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y,Ohno S, Ishida S. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh?et’s disease with infliximab.

    2012;250(7):1081-1087.

    46 Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R. Effects of infliximab in the treatment of refractory posterior uveitis of Beh?et’s disease after withdrawal of infusions.

    2010;30(5):577-581.

    47 Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y. Cytokine production profile in patients with Beh?et’s disease treated with infliximab.

    2003;24(5):210-218.

    猜你喜歡
    管理制度馬鈴薯司法
    馬鈴薯有功勞
    探討企業(yè)內(nèi)控管理制度的建立與完善
    制定法解釋中的司法自由裁量權(quán)
    法律方法(2021年4期)2021-03-16 05:34:28
    司法所悉心調(diào)解 墊付款有了著落
    非正式司法的悖謬
    食品安全公共管理制度的缺失與完善評(píng)析
    涉軍中小企業(yè)管理制度創(chuàng)新探討
    定邊馬鈴薯
    胖胖的馬鈴薯
    論司法公開的困惑與消解
    久久精品91无色码中文字幕| 国产精品av久久久久免费| 亚洲黑人精品在线| 19禁男女啪啪无遮挡网站| 在线免费观看的www视频| 美女大奶头视频| 一边摸一边做爽爽视频免费| 国产精品免费视频内射| 在线国产一区二区在线| x7x7x7水蜜桃| 亚洲成人免费av在线播放| 国产成人精品久久二区二区免费| 国产一区二区三区综合在线观看| 悠悠久久av| 日韩免费高清中文字幕av| 国产精品电影一区二区三区| 国产精品 欧美亚洲| 成人手机av| 男女床上黄色一级片免费看| 国产野战对白在线观看| 女人被躁到高潮嗷嗷叫费观| 国产精品一区二区精品视频观看| 日韩欧美在线二视频| 最近最新免费中文字幕在线| 国产黄a三级三级三级人| 老司机在亚洲福利影院| 国产日韩一区二区三区精品不卡| 中文欧美无线码| 日本 av在线| 免费在线观看影片大全网站| 9191精品国产免费久久| 夜夜夜夜夜久久久久| 亚洲中文av在线| 国产免费av片在线观看野外av| 好男人电影高清在线观看| 又黄又粗又硬又大视频| 精品国产乱子伦一区二区三区| 69精品国产乱码久久久| 免费看十八禁软件| 天堂动漫精品| 日韩欧美一区视频在线观看| 亚洲成人久久性| 亚洲欧美日韩高清在线视频| 久久久精品国产亚洲av高清涩受| 夜夜爽天天搞| 欧美成人性av电影在线观看| 亚洲国产欧美一区二区综合| 免费在线观看完整版高清| 久99久视频精品免费| 大码成人一级视频| 法律面前人人平等表现在哪些方面| 怎么达到女性高潮| 99久久99久久久精品蜜桃| 久久国产精品影院| 999久久久国产精品视频| 在线永久观看黄色视频| 天堂动漫精品| av超薄肉色丝袜交足视频| 精品一区二区三区四区五区乱码| 在线观看舔阴道视频| 又黄又粗又硬又大视频| 女人被躁到高潮嗷嗷叫费观| 男女做爰动态图高潮gif福利片 | 日韩欧美在线二视频| 久久中文字幕一级| 久久久久久大精品| 亚洲aⅴ乱码一区二区在线播放 | svipshipincom国产片| 免费久久久久久久精品成人欧美视频| 国产在线精品亚洲第一网站| xxx96com| 精品高清国产在线一区| 国产亚洲精品一区二区www| 麻豆一二三区av精品| 成人18禁高潮啪啪吃奶动态图| 午夜成年电影在线免费观看| 免费久久久久久久精品成人欧美视频| 国产一区二区三区综合在线观看| 伦理电影免费视频| 国产精品自产拍在线观看55亚洲| 免费av毛片视频| 精品国产一区二区三区四区第35| 午夜影院日韩av| 韩国精品一区二区三区| 国产成人欧美| 国产精品99久久99久久久不卡| 国产激情久久老熟女| 成年版毛片免费区| 在线观看免费午夜福利视频| 久久中文字幕一级| 亚洲成人国产一区在线观看| av欧美777| 国产在线观看jvid| 久久久久久人人人人人| 日韩大尺度精品在线看网址 | 啦啦啦在线免费观看视频4| 91麻豆av在线| 免费人成视频x8x8入口观看| 五月开心婷婷网| 男人舔女人的私密视频| 国产99久久九九免费精品| 桃色一区二区三区在线观看| 国产91精品成人一区二区三区| 国产亚洲精品第一综合不卡| 欧美精品亚洲一区二区| 一进一出抽搐gif免费好疼 | 亚洲一区高清亚洲精品| 国产高清videossex| 精品久久蜜臀av无| 日韩人妻精品一区2区三区| 91成人精品电影| 一区二区三区激情视频| 中文字幕高清在线视频| 久久精品人人爽人人爽视色| 少妇被粗大的猛进出69影院| 岛国在线观看网站| 国产成+人综合+亚洲专区| 欧美大码av| 国产精品美女特级片免费视频播放器 | 日韩一卡2卡3卡4卡2021年| 国产成人欧美在线观看| 91九色精品人成在线观看| 国产亚洲av高清不卡| 国产成人系列免费观看| 欧美日本中文国产一区发布| 男人操女人黄网站| 两个人看的免费小视频| 日韩一卡2卡3卡4卡2021年| 久久伊人香网站| 一级毛片高清免费大全| 好看av亚洲va欧美ⅴa在| 一本综合久久免费| 激情在线观看视频在线高清| 日韩一卡2卡3卡4卡2021年| 国产精品一区二区在线不卡| 一级毛片精品| 老熟妇乱子伦视频在线观看| 久久国产精品影院| 一级,二级,三级黄色视频| 午夜精品在线福利| 熟女少妇亚洲综合色aaa.| 国产亚洲精品综合一区在线观看 | 国产亚洲欧美98| 国产麻豆69| 亚洲欧美精品综合久久99| 欧美大码av| svipshipincom国产片| 成熟少妇高潮喷水视频| 欧美丝袜亚洲另类 | 80岁老熟妇乱子伦牲交| 麻豆av在线久日| 在线观看免费日韩欧美大片| www.熟女人妻精品国产| 国产1区2区3区精品| 亚洲专区国产一区二区| 久久精品aⅴ一区二区三区四区| 成在线人永久免费视频| 在线观看日韩欧美| 精品国产乱子伦一区二区三区| 亚洲欧美一区二区三区久久| 欧美亚洲日本最大视频资源| 80岁老熟妇乱子伦牲交| 国产精品日韩av在线免费观看 | 亚洲av日韩精品久久久久久密| 久久天躁狠狠躁夜夜2o2o| 国产成人欧美在线观看| 亚洲欧美一区二区三区久久| 亚洲国产欧美日韩在线播放| avwww免费| 叶爱在线成人免费视频播放| 黄片大片在线免费观看| 久久国产精品人妻蜜桃| 亚洲午夜精品一区,二区,三区| 色综合婷婷激情| 精品国产超薄肉色丝袜足j| 国产精品久久久av美女十八| 国产一区二区激情短视频| 天天添夜夜摸| 国产97色在线日韩免费| 女人爽到高潮嗷嗷叫在线视频| 三上悠亚av全集在线观看| 亚洲第一青青草原| 国产黄色免费在线视频| 国产人伦9x9x在线观看| 免费观看精品视频网站| 久久精品91蜜桃| 日韩 欧美 亚洲 中文字幕| 国产亚洲欧美在线一区二区| 母亲3免费完整高清在线观看| 亚洲精华国产精华精| 首页视频小说图片口味搜索| 91精品国产国语对白视频| 亚洲精品国产区一区二| 亚洲美女黄片视频| 国产精品自产拍在线观看55亚洲| 大型av网站在线播放| 亚洲九九香蕉| 91麻豆精品激情在线观看国产 | 精品国产乱码久久久久久男人| 国内毛片毛片毛片毛片毛片| 国产三级黄色录像| 亚洲狠狠婷婷综合久久图片| 国产一区二区三区综合在线观看| 久久中文看片网| 国产高清激情床上av| 国产高清激情床上av| 国产一区二区激情短视频| 国产精品成人在线| 法律面前人人平等表现在哪些方面| 欧美日韩瑟瑟在线播放| 国产真人三级小视频在线观看| 国产亚洲精品久久久久5区| 精品久久久久久电影网| 看黄色毛片网站| 一进一出抽搐gif免费好疼 | 视频在线观看一区二区三区| 精品久久蜜臀av无| 美女国产高潮福利片在线看| 午夜福利欧美成人| www.www免费av| 色尼玛亚洲综合影院| 激情在线观看视频在线高清| 国产高清激情床上av| 大型av网站在线播放| 夜夜夜夜夜久久久久| 香蕉久久夜色| 国产免费av片在线观看野外av| 免费人成视频x8x8入口观看| 亚洲国产中文字幕在线视频| 欧美日韩精品网址| 久久天堂一区二区三区四区| 久久久久久久久久久久大奶| 夫妻午夜视频| 亚洲熟女毛片儿| 欧美激情 高清一区二区三区| 高清毛片免费观看视频网站 | 老司机深夜福利视频在线观看| 好男人电影高清在线观看| 日韩三级视频一区二区三区| 久久久久久久精品吃奶| 日韩欧美在线二视频| 欧美不卡视频在线免费观看 | 国产1区2区3区精品| 777久久人妻少妇嫩草av网站| 亚洲成人免费电影在线观看| 亚洲va日本ⅴa欧美va伊人久久| 亚洲精品国产区一区二| 中文字幕av电影在线播放| xxxhd国产人妻xxx| 一本综合久久免费| 一本大道久久a久久精品| 热99国产精品久久久久久7| 老司机在亚洲福利影院| 国产精品免费视频内射| 少妇 在线观看| 一区二区三区激情视频| 国产亚洲精品久久久久久毛片| 亚洲伊人色综图| 欧美亚洲日本最大视频资源| 国产亚洲精品第一综合不卡| 欧美激情 高清一区二区三区| 日韩高清综合在线| 国产成人免费无遮挡视频| 自线自在国产av| 国产精品九九99| 欧美色视频一区免费| 成人18禁在线播放| 国产亚洲av高清不卡| 88av欧美| 中文字幕人妻熟女乱码| 91老司机精品| 激情视频va一区二区三区| 免费在线观看完整版高清| 两性夫妻黄色片| 国产精品偷伦视频观看了| 9色porny在线观看| 大型黄色视频在线免费观看| 国产成人精品在线电影| 老司机午夜福利在线观看视频| 777久久人妻少妇嫩草av网站| 另类亚洲欧美激情| 久久性视频一级片| 操美女的视频在线观看| 亚洲av五月六月丁香网| 免费观看人在逋| 黄色怎么调成土黄色| 一区福利在线观看| 久久中文看片网| 丰满人妻熟妇乱又伦精品不卡| 91在线观看av| 男人操女人黄网站| 美女扒开内裤让男人捅视频| 又黄又粗又硬又大视频| 成年人免费黄色播放视频| 熟女少妇亚洲综合色aaa.| 国产精品影院久久| 99香蕉大伊视频| 久久国产精品影院| 国产亚洲精品久久久久5区| 日日夜夜操网爽| 久热这里只有精品99| 欧美黄色淫秽网站| 欧美一区二区精品小视频在线| 母亲3免费完整高清在线观看| 黑人操中国人逼视频| 亚洲精品美女久久久久99蜜臀| 99久久综合精品五月天人人| 纯流量卡能插随身wifi吗| 一边摸一边抽搐一进一小说| 精品卡一卡二卡四卡免费| www.999成人在线观看| 久久久久国产一级毛片高清牌| 每晚都被弄得嗷嗷叫到高潮| 丝袜人妻中文字幕| 老司机在亚洲福利影院| 大型av网站在线播放| 好看av亚洲va欧美ⅴa在| 亚洲精品国产精品久久久不卡| 久久午夜综合久久蜜桃| 一区二区日韩欧美中文字幕| 夜夜夜夜夜久久久久| 亚洲专区中文字幕在线| 一区在线观看完整版| 变态另类成人亚洲欧美熟女 | 一个人观看的视频www高清免费观看 | 精品无人区乱码1区二区| 在线观看www视频免费| av超薄肉色丝袜交足视频| 99国产精品一区二区三区| 久久久久久久午夜电影 | 人妻丰满熟妇av一区二区三区| 国产xxxxx性猛交| 无人区码免费观看不卡| 国产高清视频在线播放一区| 一区二区三区精品91| 国产精品国产高清国产av| 中文字幕另类日韩欧美亚洲嫩草| 在线国产一区二区在线| 亚洲中文av在线| 黄色怎么调成土黄色| 亚洲精品一二三| 高清av免费在线| 亚洲国产毛片av蜜桃av| 国产区一区二久久| 久久人人精品亚洲av| 亚洲一卡2卡3卡4卡5卡精品中文| 久久精品91蜜桃| 久久精品成人免费网站| 水蜜桃什么品种好| 啪啪无遮挡十八禁网站| 欧美不卡视频在线免费观看 | 国产精品99久久99久久久不卡| 香蕉丝袜av| 日日摸夜夜添夜夜添小说| 亚洲熟妇中文字幕五十中出 | 国产亚洲欧美在线一区二区| 黄片播放在线免费| 国产一卡二卡三卡精品| 老司机福利观看| 午夜影院日韩av| aaaaa片日本免费| 韩国精品一区二区三区| aaaaa片日本免费| 日韩精品青青久久久久久| 男人操女人黄网站| 欧美一区二区精品小视频在线| 后天国语完整版免费观看| 一边摸一边做爽爽视频免费| 国产成人精品久久二区二区91| 香蕉久久夜色| 精品免费久久久久久久清纯| 国产熟女xx| 午夜福利免费观看在线| 中文字幕av电影在线播放| 欧美日本中文国产一区发布| 怎么达到女性高潮| 国产成年人精品一区二区 | 女生性感内裤真人,穿戴方法视频| 久久人妻av系列| 他把我摸到了高潮在线观看| www.熟女人妻精品国产| 久久天堂一区二区三区四区| 伦理电影免费视频| 日韩欧美三级三区| 黄片播放在线免费| 19禁男女啪啪无遮挡网站| 亚洲色图综合在线观看| 国产午夜精品久久久久久| 国产99久久九九免费精品| 日本精品一区二区三区蜜桃| 最新美女视频免费是黄的| 欧美午夜高清在线| www.熟女人妻精品国产| 美女高潮喷水抽搐中文字幕| 9色porny在线观看| 久久精品影院6| 日日夜夜操网爽| 国产一区二区在线av高清观看| 黄色a级毛片大全视频| 亚洲久久久国产精品| 国产日韩一区二区三区精品不卡| 免费在线观看完整版高清| 国产精品一区二区免费欧美| 99热只有精品国产| 黄色怎么调成土黄色| 亚洲熟妇熟女久久| 国产1区2区3区精品| 成人亚洲精品一区在线观看| 9191精品国产免费久久| 51午夜福利影视在线观看| 91九色精品人成在线观看| 亚洲狠狠婷婷综合久久图片| 搡老熟女国产l中国老女人| 国内毛片毛片毛片毛片毛片| 欧美 亚洲 国产 日韩一| 国产伦人伦偷精品视频| 国产乱人伦免费视频| 久久亚洲真实| 国产精品亚洲一级av第二区| 国产精品成人在线| 亚洲专区中文字幕在线| 国产区一区二久久| 午夜a级毛片| 正在播放国产对白刺激| 国产成年人精品一区二区 | 中文字幕人妻丝袜制服| 曰老女人黄片| 午夜免费激情av| 一区二区三区激情视频| 日韩有码中文字幕| av天堂在线播放| 国产亚洲欧美98| 日本欧美视频一区| 成人影院久久| 亚洲熟妇中文字幕五十中出 | 51午夜福利影视在线观看| 一边摸一边抽搐一进一出视频| 最近最新免费中文字幕在线| 少妇 在线观看| 在线观看午夜福利视频| 999久久久精品免费观看国产| 午夜精品久久久久久毛片777| 国产高清视频在线播放一区| 免费在线观看亚洲国产| 国产一区在线观看成人免费| 国产成人啪精品午夜网站| 久久狼人影院| 一级片免费观看大全| 精品卡一卡二卡四卡免费| 精品乱码久久久久久99久播| 狂野欧美激情性xxxx| 动漫黄色视频在线观看| 久久精品国产亚洲av高清一级| 在线观看免费高清a一片| 在线免费观看的www视频| 黑人猛操日本美女一级片| 日本五十路高清| 可以免费在线观看a视频的电影网站| 国产又爽黄色视频| 成人18禁在线播放| 天堂√8在线中文| 一级毛片高清免费大全| 少妇裸体淫交视频免费看高清 | 亚洲国产精品sss在线观看 | 国产男靠女视频免费网站| 性欧美人与动物交配| 99re在线观看精品视频| 亚洲欧洲精品一区二区精品久久久| 在线免费观看的www视频| 亚洲精品av麻豆狂野| 俄罗斯特黄特色一大片| 欧美精品亚洲一区二区| 国产色视频综合| 嫩草影视91久久| 欧美黄色淫秽网站| 另类亚洲欧美激情| 久久 成人 亚洲| 成在线人永久免费视频| 欧美日韩精品网址| 波多野结衣一区麻豆| 亚洲精品成人av观看孕妇| 欧美乱妇无乱码| 大型黄色视频在线免费观看| 91麻豆av在线| 亚洲视频免费观看视频| 在线观看一区二区三区激情| 多毛熟女@视频| 黄片小视频在线播放| 欧美最黄视频在线播放免费 | 在线播放国产精品三级| www.999成人在线观看| netflix在线观看网站| 日韩视频一区二区在线观看| 97人妻天天添夜夜摸| 亚洲五月婷婷丁香| 日本免费一区二区三区高清不卡 | 国产1区2区3区精品| 免费女性裸体啪啪无遮挡网站| 9热在线视频观看99| 国产精品久久久久久人妻精品电影| 欧美日韩精品网址| 欧美人与性动交α欧美精品济南到| 新久久久久国产一级毛片| 欧洲精品卡2卡3卡4卡5卡区| 亚洲精品美女久久av网站| 精品国产美女av久久久久小说| 女人高潮潮喷娇喘18禁视频| 久久久久九九精品影院| 丁香六月欧美| 两个人免费观看高清视频| 自拍欧美九色日韩亚洲蝌蚪91| 女人被躁到高潮嗷嗷叫费观| 久久午夜亚洲精品久久| 亚洲人成网站在线播放欧美日韩| 日本a在线网址| 精品久久久精品久久久| av有码第一页| 真人做人爱边吃奶动态| 人人妻人人爽人人添夜夜欢视频| 国产精品 欧美亚洲| av欧美777| 久久草成人影院| 精品一区二区三区视频在线观看免费 | 每晚都被弄得嗷嗷叫到高潮| 久久午夜亚洲精品久久| 精品国产亚洲在线| 成人手机av| 精品少妇一区二区三区视频日本电影| a级毛片在线看网站| 热99国产精品久久久久久7| 男女之事视频高清在线观看| 免费在线观看视频国产中文字幕亚洲| 免费高清在线观看日韩| 热re99久久国产66热| 露出奶头的视频| 咕卡用的链子| av在线天堂中文字幕 | av天堂在线播放| 97超级碰碰碰精品色视频在线观看| 好男人电影高清在线观看| 男人操女人黄网站| 国产精品久久久av美女十八| 91老司机精品| 国内毛片毛片毛片毛片毛片| 亚洲中文字幕日韩| 国产精品秋霞免费鲁丝片| 久久亚洲精品不卡| av国产精品久久久久影院| 国产伦人伦偷精品视频| 国产一区二区三区视频了| 麻豆国产av国片精品| 少妇粗大呻吟视频| 日韩一卡2卡3卡4卡2021年| 国产主播在线观看一区二区| 麻豆一二三区av精品| 亚洲国产欧美一区二区综合| 欧美一区二区精品小视频在线| 久久久国产成人精品二区 | 三级毛片av免费| 人人妻,人人澡人人爽秒播| 首页视频小说图片口味搜索| 国产成人系列免费观看| 亚洲avbb在线观看| 男女下面进入的视频免费午夜 | 免费看a级黄色片| 日本wwww免费看| 黑人巨大精品欧美一区二区蜜桃| 国产区一区二久久| 国产xxxxx性猛交| 正在播放国产对白刺激| 欧美黄色片欧美黄色片| 亚洲精品久久午夜乱码| 亚洲精品国产精品久久久不卡| 成人精品一区二区免费| 国产精品av久久久久免费| 在线十欧美十亚洲十日本专区| 免费女性裸体啪啪无遮挡网站| 一边摸一边抽搐一进一出视频| 麻豆av在线久日| 欧美日韩黄片免| 99热国产这里只有精品6| 亚洲国产欧美日韩在线播放| 久99久视频精品免费| 欧美日本亚洲视频在线播放| 久久久国产成人精品二区 | 欧美中文综合在线视频| 成人亚洲精品一区在线观看| 亚洲精品成人av观看孕妇| 日本vs欧美在线观看视频| 欧美午夜高清在线| 亚洲专区字幕在线| 欧美精品一区二区免费开放| 国产成人系列免费观看| 怎么达到女性高潮| 久久久久久久久久久久大奶| 乱人伦中国视频| 级片在线观看| 成在线人永久免费视频| 国产一区二区三区视频了| 美女扒开内裤让男人捅视频| 琪琪午夜伦伦电影理论片6080| 国产精品98久久久久久宅男小说| 国产成人一区二区三区免费视频网站| 精品一品国产午夜福利视频| 亚洲精品久久午夜乱码| 国产成人精品久久二区二区91| 伊人久久大香线蕉亚洲五| 国产av一区在线观看免费| 一个人免费在线观看的高清视频| 日韩中文字幕欧美一区二区| 性欧美人与动物交配| 国产午夜精品久久久久久| 精品少妇一区二区三区视频日本电影| 首页视频小说图片口味搜索| 成年人免费黄色播放视频|